Skip to main content
30 search results for:

Linagliptin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 24-11-2020 | Older adults | News | Article

    Age has no impact on CV outcomes with linagliptin vs glimepiride

    Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

  2. 24-09-2020 | EASD 2020 | Conference coverage | Article

    GLIMLINA: Glimepiride–linagliptin combination shows potential for HNF1A-MODY

    Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.

  3. 16-08-2019 | Linagliptin | News | Article

    Add-on linagliptin improves glycemic control in older people with type 2 diabetes

    The addition of linagliptin to stable insulin treatment improves glycemic control without increasing the risk for clinically important hypoglycemia among older individuals with type 2 diabetes, randomized trial findings suggest.

  4. 28-11-2018 | Linagliptin | News | Article

    Linagliptin preferable to insulin in majority of surgical type 2 diabetes patients

    Daily linagliptin is effective and reduces hypoglycemia risk relative to multidose insulin in type 2 diabetes patients with mild-to-moderate hyperglycemia who are undergoing non-cardiac surgery, suggest the results of a randomized controlled study.

  5. 05-10-2018 | Linagliptin | News | Article

    Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

    Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

  6. 18-04-2018 | Linagliptin | Review | Article

    The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes: Focus on linagliptin

    Aroor AR, Manrique-Acevedo C, DeMarco VG. Cardiovasc Diabetol 2018; 17: 59. doi: 10.1186/s12933-018-0704-1

  7. 26-07-2017 | Linagliptin | News | Article
    News in brief

    No short-term renal benefits with linagliptin in early diabetic kidney disease

    Linagliptin significantly improves glycemic control in individuals with type 2 diabetes and early-stage kidney disease, but fails to significantly ameliorate glomerular damage, show findings from the MARLINA-T2D trial.

  8. 03-02-2023 | Empagliflozin | News | Article

    DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

    Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

  9. 28-06-2017 | Topic page

    Linagliptin_Metformin

  10. 28-06-2017 | Topic page

    Empagliflozin_Linagliptin

  11. 05-04-2022 | Medications | At a glance | Article
    At a glance

    Medications for pediatric type 2 diabetes: What’s approved, what’s coming up?

    Linagliptin is currently undergoing testing in children and adolescents , in a trial also testing the sodium-glucose cotransporter (SGLT)2 inhibitor empagliflozin.

  12. 11-06-2019 | Linagliptin | News | Article

    CAROLINA shows neutral cardiovascular profile for modern sulfonylurea

    The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

  13. 16-08-2018 | DPP-4 inhibitors | Review | Article

    Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

    Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

  14. 22-05-2019 | Sulfonylureas | Editorial | Article

    The CAROLINA trial: Make or break for sulfonylureas?

    Dose adjustment requirement Linagliptin does not require dose adjustment.

  15. 03-03-2017 | Linagliptin | News | Article

    DPP-4 inhibition may reduce vascular stiffness

    A randomized trial shows that the dipeptidyl peptidase-4 inhibitor linagliptin has a rapid and reversible beneficial effect on arterial stiffness.

  16. 12-06-2019 | DPP-4 inhibitors | News | Article

    CARMELINA findings confirmed in highest CV risk subgroups

    They also showed that progression to albuminuria was reduced with linagliptin versus placebo in all but the lowest eGFR subgroup, and that there was no increased risk for hospitalization for heart failure by age or renal function.

  17. 06-12-2016 | Empagliflozin/Linagliptin | News | Article

    Empagliflozin effective as add-on to dual oral therapy

    The sodium–glucose cotransporter 2 inhibitor empagliflozin significantly improves glycemic control in patients with type 2 diabetes who are already taking linagliptin and metformin, shows a randomized trial.

  18. 17-04-2018 | DPP-4 inhibitors | At a glance | Article
    Updated July 2019

    Round-up of the DPP-4 inhibitor CV outcome trials

    News story |  Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes CAROLINA Medications: linagliptin, glimepiride Patient population: N=6033, at high risk or with established cardiovascular disease (42%) The CAROLINA trial was designed to test whether a DPP-4 inhibitor would have a more favorable CV profile than a sulfonylurea.

  19. 29-11-2012 | Post-transplant diabetes mellitus | Review | Article

    Management of post-transplant diabetes

    Therasse A, Wallia A, Molitch ME. Curr Diab Rep 2013; 13: 121–129. doi: 10.1007/s11892-012-0346-8

  20. 29-06-2020 | SGLT2 inhibitors | News | Article

    CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

    Sitagliptin was the most common DPP-4 inhibitor (49% of total exposure time), followed by linagliptin (20%), and saxagliptin (11%).

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.